116 results
Page 2 of 6
8-K
EX-10.1
55z3vxl9
31 Jul 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
8:28am
8-K
EX-99.1
jjjh3ftyc
31 Jul 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
8:28am
424B5
raffj
31 Jul 23
Prospectus supplement for primary offering
8:23am
8-K
EX-99.1
i5vx05x6uz9g
27 Jul 23
55% objective response rate; 23% complete response rate in locally advanced cSCC
7:30am
8-K
EX-10.1
w8mhcrk1i jss
13 Jun 23
Departure of Directors or Certain Officers
7:00am
424B5
o4p5rzd4t1qh2bz dscy
24 May 23
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
uem955yhe9fcw96ynv
24 May 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
5:24pm
8-K
EX-10.1
sdgnjlm2jgbc
24 May 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
5:24pm
8-K
EX-99.1
3cwn8r0s308zjt shnio
15 May 23
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
4:21pm
8-K
EX-10.1
p7mew
4 Apr 23
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
6:05am
8-K
EX-99.1
rq4ydptznx2fc6nne
4 Apr 23
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
6:05am
424B5
xggw kxykdl
4 Apr 23
Prospectus supplement for primary offering
6:03am
8-K
EX-99.1
rbrvxn2yl1e 5is
31 Mar 23
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
6:00am
8-K
EX-10.1
73ymqf6xqyo
16 Dec 22
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
7:05am
8-K
EX-99.1
pz7y k8ea
16 Dec 22
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
7:05am